Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNEW: Elamipretide in Dry Age-Related Macular Degeneration
NCT06373731Phase 3Active, not recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of elamipretide in age-related macular degeneration (AMD), sponsored by Stealth BioTherapeutics. Started May 2024; status: active, not recruiting.
02
Drugs
elamipretide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT06373731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373731.